IMRA - Dosing underway in mid-stage study of IMR-687 in beta-thalassemia

Imara (IMRA) has dosed the first patient in the Forte Phase 2b trial of IMR-687 for adult patients with beta-thalassemia, a rare inherited red blood cell disorder. Beta-thalassemia presents as a spectrum of disease, with patients categorized based on hemoglobin levels, genotype and clinical manifestations.The global, randomized, double-blind, placebo-controlled, multicenter Forte Phase 2b trial will evaluate the safety and tolerability of IMR-687 in ~120 adult beta-thalassemia patients.Patient randomization will be deposied by transfusion dependence ((TDT)) or non-transfusion dependence ((NTDT)) and weight-based dosing will be employed to optimize drug exposure and tolerability.For TDT patients, the clinical trial will also evaluate the effect of IMR-687 vs placebo in reducing the average number of days between red blood cell transfusions and change in iron load rate as a result of transfusion.For NTDT patients, the effect of IMR-687 vs placebo on fetal hemoglobin as well as on anemia will also be evaluated.The trial will also examine pharmacokinetic and additional exploratory

For further details see:

Dosing underway in mid-stage study of IMR-687 in beta-thalassemia